Chemokine axes such as CCL2-CCR2 and CCL5-CCR5 drive further recruitment to adipose tissue, and in part provides the rationale for their dual CCR2-CCR5 antagonism as a therapeutic approach to resolve inflammation and prevent fibrosis progression in NAFLD (75). This evidence concerns the gene CCR5 and metabolic dysfunction-associated steatotic liver disease.